Time for a fight back on structured product coverage?

clock • 5 min read

Jamie Smith, chairman of the UK Structured Products Association, asks: Is it time the consumer press were made more accountable for their coverage of structured products?

As well as turning to advisers and their banks for financial guidance, many consumers look to the finance sections of the national newspapers. Readers place high confidence in the journalists’ thoughts and often view them as financial experts. That is why it is again extremely frustrating to see one of the most widely distributed national newspapers attempt to attract readers by publishing sensational stories with little evidence or clarity around the content. On 6 March, the Daily Mail published an article about structured products (‘Savers lured into a £9bn gamble’), criticising the...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now


Already an Investment Week


More on Specialist

While thematic funds offer diversification and a specialist knowledge base, investors must also consider the sensitivity to real bond yields inherent in these funds.

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
Deal volumes fell last year as rising interest rates brought the end of cheap money

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Ali H. Munawar, CEO of Pledge Therapeutics

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read